Bristol Myers Squibb Reports observational Data for Gene therapy in Crohn's disease

Bristol Myers Squibb today announced observational results for gene therapy in patients with Crohn's disease. The study demonstrated that gene therapy improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of Crohn's disease and support the continued development of gene therapy in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.